Chengde Wu from 2511 Lansing Cir, Pearland, TX 77584, age 61, Phone: 713 436-9476

Us Patents

N-Aryl Thienyl-, Furyl-, And Pyrrolyl-Sulfonamides And Derivatives Thereof That Modulate The Activity Of Endothelin
view source
US Patent:

6342610, Jan 29, 2002
Filed:

Nov 7, 1997
Appl. No.:

08/913331
Inventors:

Ming Fai Chan - San Diego CA
Chengde Wu - Houston TX
Bore Gowda Raju - Sugar Land TX
Timothy Kogan - Sugar Land TX
Erik Joel Verner - Foster City CA
Rosario Silvestre Castillo - San Diego CA
Venkatachalapathi Yalamoori - San Diego CA
Adam Kois - San Diego CA
Assignee:

Texas Biotechnology Corp. - Houston TX
International Classification:

C07D20736
US Classification:

548543, 514421, 514441, 514470, 548550, 549 65, 549470
Abstract:

Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

Benzenesulfonamides And The Use Thereof To Modulate The Activity Of Endothelin
view source
US Patent:

6376523, Apr 23, 2002
Filed:

Nov 12, 1999
Appl. No.:

09/439802
Inventors:

Ming Fai Chan - San Diego CA
Bore Gowda Raju - San Diego CA
Adam Kois - San Diego CA
Erik Joel Verner - San Diego CA
Chengde Wu - San Diego CA
Rosario Silvestre Castillo - San Diego CA
Venkatachalapathi Yalamoori - San Diego CA
Assignee:

Texas Biotechnology Corporation - Houston TX
International Classification:

A61K 3142
US Classification:

514380, 514312, 548246, 546153
Abstract:

N-(5-isoxazolyl)benzenesulfonamides and N-(3-isoxazolyl)benzenesulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(5-isoxazolyl)biphenylsulfonamides and N-(3-isoxazolyl)biphenylsulfonamides and methods for inhibiting the binding of an endothelin peptide to an endothelin receptor or increasing the activity of endothelin peptides by contacting the receptor with a sulfonamide are provided. N-isoxzolyl-4-biphenylsulfonamides are particularly preferred. These compounds exhibit activity as endothelin receptor B antagonists. Methods for treating endothelin-mediated disorders, particularly inflammatory diseases, such as asthma, by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

N-Heteroaryl Aryl-Substituted Thienyl-Furyl-And Pyrrolyl-Sulfonamides And Derviatives Thereof That Modulate The Activity Of Endothelin
view source
US Patent:

6420567, Jul 16, 2002
Filed:

Sep 26, 1997
Appl. No.:

08/938325
Inventors:

Chengde Wu - Houston TX
Bore Gowda Raju - Sugarland TX
Timothy Kogan - Sugarland TX
Natalie Blok - Houston TX
Assignee:

Texas Biotechnology Corporation - Houston TX
International Classification:

C07D26104
US Classification:

548245, 514311, 514312, 514313, 514314, 514378, 514379, 514380, 548244, 548247
Abstract:

Thienyl-, furyl- and pyrrolyl-sulfonamides, formulations of pharmaceutically-acceptable salts thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit the activity of endothelin are also provided.

Sulfonamides For Treatment Of Endothelin-Mediated Disorders
view source
US Patent:

6432994, Aug 13, 2002
Filed:

Mar 27, 2000
Appl. No.:

09/403599
Inventors:

Chengde Wu - Houston TX
Natalie Blok - Houston TX
Timothy Kogan - late of Escondido CA
Karin Keller - Houston TX
Patricia Woodard - Escondido CA
Assignee:

Texas Biotechnology Corporation - Houston TX
International Classification:

A61K 3142
US Classification:

514380, 548245, 548246, 548247
Abstract:

Thienyl-, furyl- and pyrrolyl-sulfonamides, pharmaceutically-acceptable salts of sulfonamides, formulations of salts and the sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides using the formulations and sulfonamides are provided. In particular, formulations of sodium salts of N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides are provided. A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic phase.

Formulation Of Sulfonamides For Treatment Of Endothelin-Mediated Disorders
view source
US Patent:

6458805, Oct 1, 2002
Filed:

Feb 23, 2001
Appl. No.:

09/792237
Inventors:

Natalie Blok - Houston TX
Chengde Wu - Houston TX
Patricia Woodard - Sugarland TX
Karin Keller - Houston TX
Timothy Kogan - Sugarland TX
Assignee:

Texas Biotechnology Corporation - Houston TX
International Classification:

A61K 3147
US Classification:

514313, 514314, 514340, 514342
Abstract:

Formulations of pharmaceutically-acceptable salts of thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides using the formulations are provided. In particular, formulations of sodium salts of N-(isoxazolyl)-thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)-pyrrolylsulfonamides and methods using these sulfonamide salts for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide salt are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamide salts or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

Benzenesulfonamides And The Use Thereof To Modulate The Activity Of Endothelin
view source
US Patent:

6541498, Apr 1, 2003
Filed:

Dec 27, 2000
Appl. No.:

09/749716
Inventors:

Ming Fai Chan - Encinitas CA
Bore Gowda Raju - Fremont CA
Adam Kois - San Diego CA
Erik Joel Verner - Foster City CA
Chengde Wu - Pearland TX
Rosario Silvestre Castillo - San Diego CA
Venkatachalapathi Yalamoori - San Diego CA
Vitukudi Narayanaiyengar Balaji - Bangalore, IN
Kalyanaraman Ramnarayan - San Diego CA
Assignee:

Texas Biotechnology - Houston TX
International Classification:

A61K 3142
US Classification:

514380
Abstract:

N-(5-isoxazolyl)benzenesulfonamides and N-(3-isoxazolyl)benzenesulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(5-isoxazolyl)biphenylsulfonamides and N-(3-isoxazolyl)biphenylsulfonamides and methods for inhibiting the binding of an endothelin peptide to an endothelin receptor or increasing the activity of endothelin peptides by contacting the receptor with a sulfonamide are provided. N-isoxzolyl-4-biphenylsulfonamides are particularly preferred. These compounds exhibit activity as endothelin receptor B antagonists. Methods for treating endothelin-mediated disorders, particularly inflammatory diseases, such as asthma, by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

Sulfonamides And Derivatives Thereof That Modulate The Activity Of Endothelin
view source
US Patent:

6632829, Oct 14, 2003
Filed:

Nov 5, 2001
Appl. No.:

10/011610
Inventors:

Chengde Wu - Houston TX
Bore Gowda Raju - Sugarland TX
Timothy Kogan - Sugarland TX
Natalie Blok - Houston TX
Patricia Woodard - Sugarland TX
Assignee:

Texas Biotechnology Corp. - Houston TX
International Classification:

A61K 3142
US Classification:

514361, 514380, 424489
Abstract:

Thienyl-, furyl- and pyrrolyl-sulfonamides, formulations of pharmaceutically-acceptable salts thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit the activity of endothelin are also provided.

Sulfonamides For Treatment Of Endothelin-Mediated Disorders
view source
US Patent:

6683103, Jan 27, 2004
Filed:

Dec 20, 2001
Appl. No.:

10/029561
Inventors:

Chengde Wu - Houston TX
Natalie Blok - Houston TX
Timothy Kogan - late of Escondido CA
Karin Keller - Austin TX
Assignee:

Texas Biotechnology Corporation - Houston TX
International Classification:

A61K 3142
US Classification:

514378, 548247, 424451, 424464, 424489, 424493
Abstract:

Thienylsulfonamides and their pharmaceutically acceptable derivatives, pharmaceutical compositions, articles of manufacture, combinations, lyophilized powders and methods for the treatment of endothelin diseases using these formulations and sulfonamides are provided. A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic phase.